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	 Polyethylene	glycol	2000	(PEG)	entrapped,	bovine	serum	albumin	(BSA)	microspheres	were
prepared	and	optimized.	These	microspheres	were	 then	analyzed	 to	understand	 the	 stealth
effect	to	the	microspheres	imparted	by	incorporated	polyethylene	glycol	(PEG).	Microsphere
preparations	 (formulations)	were	 studied	 for	 particle	 size,	 zeta	 potential,	 free	BSA	 content,
and	 in‐vitro	 uptake	 by	 human	 micro‐vascular	 endothelial	 cells	 (HMECs).	 The	 results
demonstrate,	a	formulation	containing	37.5	%	PEG	(w/w)	exhibits	an	acceptable	particle	size
of	 <5	 µm,	 good	 suspendibility	 with	 zeta	 potential	 of	 ‐35	 mV,	 and	 confers	 some	 degree	 of
stealth	 property	 to	 the	 microspheres.	 These	 non‐toxic,	 biodegradable	 and	 long	 circulating
microspheres	 have	 the	 potential	 to	 be	 used	 for	 extended	 intravenous	 (IV)	 drug	 delivery.
Statistical	analysis	done	by	ANOVA	and	results	with	p<0.05	were	considered	significant.	
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1.	Introduction	
	
Cross‐linked	albumin	microspheres	are	a	potential	delivery	
method	 for	 slow	 release	 of	 drugs	 or	 antigens	 to	 the	 targeted	
sites	 [1‐7].	 Bovine	 serum	 albumin	 microspheres	 have	 been	
extensively	 investigated	 in	 controlled	 release	 drug	 delivery	
systems	since	introduced	by	Kramer	[8].	Release	of	a	drug	from	
the	 albumin	 microspheres	 can	 be	 manipulated	 using	 the	
amount	 of	 BSA,	 size	 and	 suspendibility	 of	 the	 microspheres,	
and	 most	 effectively,	 the	 degree	 of	 cross‐linking	 [9].	 Earlier	
methods	 of	 surface	 cross‐linking	 could	 control	 the	 release	 as	
long	 as	 the	 surface	 was	 intact.	 Enzymes	 and	 other	 in‐vivo	
factors	 quickly	 overcome	 the	 surface	 barrier.	 The	 more	
recently	 developed	 matrix	 cross	 linking	 has	 an	 added	
advantage	 where	 cross‐linkages	 among	 the	 ‐NH2	 (amine)	
groups	 takes	 place	 in	 the	 entire	 matrix,	 that	 allows	 drugs	 to	
slowly	 release	 in	 the	 surrounding	 environment.	 These	
microspheres	 are	 easily	 phagocytosed	 and	 act	 as	 an	 excellent	
delivery	 vehicle	 for	 intercellular	 delivery.	 However,	 for	 a	
systemic	 drug	 delivery,	 longer	 circulating	 microspheres	 are	
required.	Polyethylene	glycol	has	demonstrated	 imparting	 the	
stealth	 property	 by	 avoiding	 opsonization	 in	 various	 studies	
pertaining	 to	 liposomal	 preparations	 [10‐12]	 and	 drug	
molecules	 [13].	 PEG	 is	 non‐toxic	 and,	 after	 cleavage	 in	 vivo	
from	 the	 PEG‐drug	 conjugate,	 free	 PEG	 cleared	 rapidly	 out	 of	
the	 body	 by	 the	 kidneys.	 The	 stealth	 effect	 was	 achieved	 by	
covalently	linking	PEG	to	the	drug	molecules	[14,15].	However,	
due	 to	 large	 size	 of	 modified	 drug–PEG	molecules,	 they	 have	
difficulty	in	crossing	the	cell	membrane,	hence	this	approach	is	
not	advantageous.	On	the	other	hand,	if	a	delivery	vehicle	(e.g.,	
microspheres)	can	be	made	stealth	with	drug	inside	them,	then	
drug	 can	 be	 released	 for	 a	 longer	 period	 of	 time	 in	 the	
circulation.	There	are	no	reports	of	evaluating	stealth	effect	of	
PEG	on	BSA	microspheres.	One	approach	of	covalently	 linking	
the	 PEG	 to	 BSA	 and	 subsequently	 making	 microspheres	 was	
likely	 to	 constitute	 stealth	microspheres	 [16].	However,	 these	
microspheres	 rapidly	 disintegrate	 in	 the	 solution	 and	 do	 not	
provide	an	appropriate	vehicle	for	sustained	drug	delivery.	
In	the	present	study,	we	explore	the	possibility	of	providing	
stealth	 property	 to	 the	 microspheres	 by	 incorporating	 PEG	
2000	 (known	 for	 prolonging	 plasma	 residence	 time	 of	 the	
liposomal	formulations	[17])	into	the	BSA	prior	to	cross‐linking	
of	 the	 BSA	 matrix.	 The	 purpose	 is	 to	 entrap	 PEG	 without	
covalently	 binding	 to	 the	 drug	 molecules	 or	 BSA.	 This	 is	
accomplished	by	cross‐linking	BSA	in	the	presence	of	PEG	and	
subsequently	 obtaining	 microspheres	 by	 a	 spray	 drying	
process.	 Different	 concentrations	 of	 PEG	 were	 tested	 and	
investigated	 for	 free	 BSA	 present	 in	 the	 microspheres	 to	
optimize	 the	 process.	 Microspheres	 were	 analyzed	 and	
characterized	 by	 particle	 size	 determination,	 zeta	 potential	
measurement,	infra–red	spectroscopy	and	differential	scanning	
calorimetry.	 	 Surface	 characteristics	 of	 microspheres	 were	
studied	 by	 electron	 microscopy.	 For	 investigating	 the	 stealth	
property	we	employed	vascular	endothelial	cells,	which	are	the	
first	one	to	come	in	contact	with	microspheres	when	delivered	
intravascularly.	 	 In	 the	 present	 study,	 we	 considered	 Human	
Micro‐vascular	 Endothelial	 Cells	 (HMECs),	 a	 known	 stable	
phagocytic	cell	line,	[18]	to	determine	the	stealth	effect	of	PEG	
present	in	the	microspheres.	
	
2.	Experimental	
	
2.1.	Materials	
	
Bovine	 serum	 albumin,	 polyethylene	 glycol	 2000	 and	
glutraldehyde	(GA)	were	obtained	 from	Sigma	(St.	Louis,	MO).	
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HMECs	 and	 the	 nutrient	 media	 [MCDB	 131,	 supplemented	
(EBM)]	 were	 obtained	 from	 CDC	 (Atlanta,	 GA).	 HMECs	 were	
grown	 in	 75	 cm2	 flasks,	 subcultured	 in	 24‐well	 tissue	 culture	
plates	obtained	from	Fisher	Scientific,	and	incubated	at	37	°C	in	
the	presence	of	5%	CO2	for	24	hrs	(80‐90%	confluence).	
	
2.2.	Methods	
	
2.2.1.	Preparation	of	microspheres	
	
Seven	 formulations	 (A	 to	 G,	 Table	 1)	 containing	 different	
amounts	of	PEG	ranging	from	0.0–66.7%	(w/w,	relative	to	BSA)	
were	 prepared	 in	 5%	 BSA	 (w/v)	 and	 cross‐linked	 by	
glutraldehyde	 for	 18	 hrs	 at	 room	 temperature	 as	 described	
previously	 [1‐7].	 Excess	 glutraldehyde	 was	 neutralized	 with	
sodium	bisulfite.	Cross‐linked	solutions	were	spray‐dried	using	
a	 Büchi	 mini	 spray	 dryer	 (Büchi	 191).	 Microspheres	 were	
aspirated	through	a	chamber	where	they	were	cooled	down	to	
a	 lower	 outlet	 temperature	 and	 deposited	 into	 a	 product	
container	through	a	cyclone.	The	prepared	microspheres	were	
collected	and	refrigerated	at	5	°C	until	further	use.	
	
Table	 1.	 Free	 BSA	 amount	 in	 cross‐linked	 microspheres	 containing	 PEG.	
Formulations	A,	B,	C,	D,	E,	F,	and	G	were	prepared	with	the	addition	of	0.00,	
9.09,	 16.67,	 28.57,	 37.50,	 50.00	 and	 66.67	%	 of	 PEG	 (w/w	with	 respect	 to	
BSA)	in	5%	(w/v)	BSA	aqueous	solution.	
Formulations	 %	PEG	 %	BSA	 %		of	free	BSA	
A	 0.0	 100.0	 17.8
B	 9.1	 90.9	 17.3
C	 16.7	 83.3	 12.6
D	 28.6	 71.4	 16.9
E	 37.5	 62.5	 16.8
F	 50.0	 50.0	 91.8
G	 66.7	 33.3	 106.6
	
2.2.2.	Analysis	of	free	BSA	
	
The	purpose	of	this	study	was	to	evaluate	the	effect	of	PEG	
on	 the	 cross‐linking	 of	 BSA	 in	 the	 solution.	 Free	 BSA	 which	
could	not	be	cross‐linked	due	to	the	presence	of	PEG	remained	
soluble	 in	water	 and	was	 quantified	 by	 a	 spectrophotometer.	
Microspheres	 equivalent	 to	 20	 mg	 of	 BSA	 content	 were	
suspended	 in	 10	 ml	 of	 deionized	 water	 at	 37	 °C	 for	 1	 hr,	
vortexed	and	centrifuged	for	15	minutes	at	3000	rpm.	Samples	
of	 5	 mL	 clear	 supernatant	 were	 taken	 and	 absorbance	 was	
recorded	by	a	Perkin	Elmer	Spectrophotometer	at	the	277	nm	
wavelength.	 Standard	 solutions	 of	 BSA	 with	 concentrations	
ranging	 from	0.032	mg/mL‐4.000	mg/mL	of	BSA	 in	deionized	
water	 were	 freshly	 prepared	 and	 also	 read	 at	 the	 277	 nm	
wavelength.	 The	 amount	 of	 free	 BSA	 present	 in	 the	
microsphere	formulations	was	calculated.	
	
2.3.	Physical	characterizations	
	
2.3.1.	Particle	size	
	
The	size	of	the	microspheres	plays	a	significant	role	in	the	
uptake	 by	 phagocytes	 and	 delivery	 of	 drugs.	 Particle	 size	
analysis	 was	 performed	 using	 a	 Spectrex	 Laser	 Particle	
Counter,	 PS‐2000.	 Approximately	 0.5	 mg	 of	 microspheres	 of	
each	formulation	were	suspended	in	7	mL	of	filtered	deionized	
water	 in	separate	10	mL	vials.	The	vials	were	vortexed	 for	10	
seconds	and	placed	in	the	laser	particle	counter	to	measure	the	
particle	size.	
	
2.3.2.	Zeta	potential		
	
Zeta	potential	determined	in	phosphate	buffer	saline	(PBS)	
of	pH	=	7.4	(PBS)	by	using	a	Malvern	Zeta‐sizer.		
	
	
	
	
2.3.3.	Fourier	transform	infrared	spectroscopy	(FT‐IR)	
	
The	 FT‐IR	 was	 used	 to	 identify	 and	 determine	 the	
characteristic	functional	groups	in	PEG,	BSA	and	microspheres	
and	 experiments	were	 carried	 out	 using	 standard	 protocol	 of	
Perkin	 Elmer	 FT‐IR.	 We	 used	 FT‐IR	 to	 identify	 PEG	 in	 the	
microspheres	 and	 to	 investigate	 if	 there	 was	 interaction	
between	 PEG	 and	 BSA.	 A	 small	 amount	 of	 BSA,	 PEG	 and	
microsphere	 formulation	 (all	 individually)	 was	 placed	 on	 the	
FTIR	 crystal	 and	 the	 spectrum	recorded	 from	500‐4000	wave	
numbers	(cm‐1).		
	
2.3.4.	Differential	scanning	calorimetry	(DSC)	
	
The	 DSC	 was	 used	 to	 determine	 the	 compatibility	 of	
excepients.	It	is	also	used	to	notice	heat	induced	changes	in	the	
polymer.	We	employed	this	tool	to	determine	if	PEG	affects	the	
cross‐linking	 of	 BSA.	 DSC	 was	 performed	 in	 DSC	 Q	 100	 by	
weighing	 ~5	 mg	 of	 each	 of	 the	 microsphere	 formulations	 in	
standard	 aluminum	 pans	which	were	 non‐hermetically	 crimp	
closed	using	TA's	blue	DSC	sample	press.	The	encased	sample	
and	 reference	 pan	 were	 placed	 on	 the	 heating	 stages	 in	 the	
instrument	and	were	heated	from	27.5	°C	to	325°C	with	a	ramp	
speed	of	5	°C	per	minute.			
	
2.3.5.	Scanning	electron	microscopy	(SEM)	
	
The	 SEM	 was	 carried	 out	 at	 Centers	 for	 Disease	 Control	
(CDC,	 Atlanta,	 GA)	 using	 an	 Environmental	 Scanning	 Electron	
Microscope	 XL	 30	 ESEM	 manufactured	 by	 the	 FEI	 Company,	
Hillsboro,	 Oregon.	 This	 Environmental	 Scanning	 Electron	
Microscope	 achieves	 high	 magnification	 with	 excellent	
resolution.	 Microsphere	 samples	 were	 placed	 on	 holders	 and	
coated	with	gold	 in	Sputter	Coater	 to	achieve	a	 thickness	of	2	
nm.	 Coated	 samples	 were	 placed	 in	 the	 ESEM	 chamber	 and	
vacuum	 was	 applied.	 Pictures	 were	 taken	 at	 around	 40,000x	
magnifications	 to	 visualize	 the	 surface	 characteristics	 of	
microspheres.	
	
2.3.6.	In‐vitro	cell	uptake	study	
	
HME	 cells	 were	 grown	 and	 maintained	 in	 MCDB	 131	
complete	 medium	 at	 37	 °C	 in	 the	 presence	 of	 5%	 carbon	
dioxide.	 Microspheres	 were	 labelled	 with	 fluorescamine	 dye	
[19,20]	 as	 per	 standard	 product	 information	 sheet	 F9015	
provided	 by	 Sigma	 (Milwaukee,	 WI).	 Labeled	 microspheres	
were	 added	 to	 the	 HME	 cells	 at	 a	 ratio	 of	 10:1	 and	 the	 cell	
suspension	was	 evenly	made	 in	 the	 culture	 plates.	 At	 various	
time	 points	 (0.5‐48	 hrs)	 cells	 were	 washed	 to	 remove	
unattached	and	unphagocytosed	microspheres.	HME	cells	were	
observed	 under	 fluorescence	 microscopy	 to	 determine	 the	
microspheres	 uptake.	HME	 cells	were	 lysed	with	 triton‐X	 and	
fluorescence	was	measured	by	using	Tecan	Genius	fluorometer	
at	 the	 excitation	 wavelength	 of	 485	 nm	 and	 the	 emission	
wavelength	of	535	nm	and	the	percent	uptake	of	microspheres	
was	calculated.		
	
3.	Results	and	discussion	
	
3.1.	Free	BSA	analysis	
	
Table	 1	 shows	 formulations	 F	 and	 G	 containing	 high	 PEG	
concentrations	 of	 50.0%	 and	 66.7%	 (w/w),	 respectively,	
resulting	 in	 high	 amounts	 of	 free	 BSA	 in	 the	 microspheres.	
These	microsphere	formulations	were	fragile	and	disintegrated	
in	water	very	easily,	forming	an	almost	clear	solution	within	a	
few	minutes.		
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(a)	
	
(b)	
Figure	1.		SEM	of	microsphere	formulations	showing	surface	characteristics	of	cross‐linked	BSA	microspheres	at	magnification	of	x	
40,000;	(a)	Formulation	A,	BSA	microspheres	without	PEG	2000	and	(b)	Formulation	E,	BSA	microspheres	with	PEG	2000.	
	
	
This	 phenomenon	 could	 be	 due	 to	 the	 interference	 by	 a	
high	 amount	 of	 PEG	 hindering	 the	 cross‐linking	 of	 BSA	
resulting	 in	 no	 or	 minute	 cross‐linking	 among	 the	 BSA	
molecules,	hence	a	high	yield	of	free	BSA	in	the	formulation.	We	
noticed	the	percent	recovery	exceeds	100%	for	formulation	G,	
which	means	 the	 sample	weight	 taken	equivalent	 to	20	mg	of	
BSA	actually	contains	more	BSA	than	anticipated.	This	could	be	
due	 to	 the	 PEG	 containing	 a	 very	 high	 number	 of	 associated	
water	 molecules	 (hydration	 number	 136±4)	 and	 loss	 of	 PEG	
(and	 associated	 water)	 during	 the	 spray	 drying	 process,	
resulting	in	more	BSA	in	the	final	product	than	estimated.	Data	
indicates	 PEG	 content	 higher	 than	 37.5	%	 is	 unsuitable,	 as	 it	
interferes	 with	 cross‐linking	 and	 may	 result	 in	 burst	 release.	
Based	 upon	 this	 data,	 formulation	 F	 and	 G	 were	 found	
unsuitable	for	our	study	and	further	analysis	not	performed.	
	
3.2.	Particle	size	and	zeta	potential	
	
Table	2	shows	formulations	A	to	E	have	a	mean	particle	size	
of	 <5	 µm	 and	 are	 ideal	 for	 encapsulation	 and	 drug	 delivery,	
while	Table	3	 shows	 that	 zeta	potential	 is	 high	 and	 results	 in	
good	 dispersion	 of	 the	microspheres	 in	 PBS.	 This	 implies	 the	
microspheres	 will	 remain	 in	 suspension	 for	 a	 long	 time	 and	
with	low	chance	of	forming	aggregates	and	potentially	clogging	
the	capillaries.	
	
Table	2.	Particle	size	of	various	formulations	evaluated.	
Measurements	
Formulations	
A	 B C	 D	 E
1	 3.11	 3.60 3.74	 3.80	 3.66
2	 3.05	 3.13 3.50	 3.71	 3.13
3	 3.03	 3.07 3.46	 3.57	 3.07
Average	size	(µm)	 3.06	 3.48 3.57	 3.69	 3.29
SD	 0.04	 0.29 0.15	 0.12	 0.32
	
Table	3.	Zeta	potential	of	the	formulations.	
Measurement	
Formulations	
A	(mV)	 B	(mV)	 C	(mV)	 D	(mV)	 E	(mV)
1	 ‐34.23	 ‐31.79	 ‐32.73	 ‐31.89	 ‐33.27
2	 ‐33.83	 ‐30.39	 ‐31.83	 ‐34.03	 ‐37.79
3	 ‐38.46	 ‐30.92	 ‐33.86	 ‐34.59	 ‐35.91
Average	 ‐35.51	 ‐31.03	 ‐32.81	 ‐33.50	 ‐35.66
SD	 2.57	 0.71	 1.02	 1.42	 2.27
	
3.3.	Scanning	electron	microscopy	
	
The	 Figure	 1	 shows	 the	 SEM	 images	 of	 the	microspheres	
and	 highlights	 the	 surface	 characteristics.	 The	 BSA	
microspheres	 without	 PEG	 2000	 (Figure	 1a)	 show	 smooth	
topography	whereas	BSA	microspheres	with	PEG	2000	show	a	
wrinkled	topography;	(Figure	1b).	This	is	indicative	of	the	fact	
that	 PEG	 2000	 is	 exposed	 at	 the	 surface	 of	 the	microspheres	
that	 when	 comes	 in	 contact	 with	 water,	 will	 form	 hydration	
layer	 around	 the	 microspheres,	 thus	 imparting	 the	 desired	
stealth	property.	
	
3.4.	Differential	scanning	calorimetry	
	
The	DSC	showed	no	variability	in	the	melting	curve	of	BSA	
in	the	formulations	(Figure	2).	Although	it	 is	obvious	that	PEG	
has	no	cross‐linking	sites,	DSC	further	confirmed	that	PEG	had	
no	 chemical	 interactions	 with	 BSA	 or	 to	 itself	 by	 the	 cross‐
linker	(GA).	
	
 
	
Figure	 2. DSC	 profile	 of	 the	 PEG	 2000,	 formulation	 A	 (BSA	 only	
microspheres)	and	formulation	E	(BSA	microspheres	with	PEG	2000).	
	
3.5.	Fourier	transform	infrared	spectroscopy	
	
FT‐IR	of	the	formulations	indicate	that	the	BSA	and	PEG	are	
chemically	compatible,	and	the	presence	of	PEG	does	not	alter	
the	 course	 of	 BSA	 cross‐linking.	 FTIR	 spectroscopy	 is	 a	
powerful	 analytical	 tool,	 able	 to	 quickly	 identify	 complex	
molecules	 bearing	 a	 rich	 assortment	 of	 IR	 bands.	 It	 is	
interesting	 to	 note	 that	 formulation	 A	 (cross‐linked	 BSA	with	
no	PEG)	shows	very	strong	carbonyl	and	amine	group	peaks	at	
1532	cm‐1	and	1645	cm‐1,	respectively	(Figure	3).	These	strong	
peaks	are	due	to	the	presence	of	encapsulating	matrix	BSA	that	
is	 a	 large	 protein	 containing	 great	 number	 of	 amine	 and	
carbonyl	groups.	Similarly	formulation	E,	that	compose	of	PEG	
modified	 cross‐linked	 BSA	 encapsulating	 material,	 not	 only	
shows	 the	 characteristic	 peaks	 of	 BSA	 (vide	 supra)	 but	 also	
contains		a		strong		absorption		band		at		1106		cm‐1	due	to	ether		
	
128	 Angra	et	al.	/	European	Journal	of	Chemistry	2	(2)	(2011)	125‐129	
	
	
Table	4.	Percent	uptake	of	various	microsphere	formulations	by	HMECs	shows	the	comparative	uptake	of	formulations	A,	B,	C,	D,	and	E	containing	0.00,	9.09,	
16.67,	28.57,	and	37.50%	PEG	(w/w)	in	5%	BSA	solution,	respectively.		
Percent	Uptake	of	Microspheres
Formulations	
Time	in	hours p‐value	
<0.05	0.5	 1	 2	 4 8 12 24	 48	
A	 7.0%	 7.8%	 8.2%	 8.2% 8.3% 8.4% 8.4%	 8.4%	 0.73
B	 6.9%	 7.9%	 8.0%	 8.1% 8.3% 8.3% 8.3%	 8.2%	 0.75
C	 7.1%	 7.6%	 8.0%	 8.1% 8.2% 8.3% 8.3%	 8.2%	 0.59
D	 6.4%	 7.6%	 7.7%	 7.6% 8.1% 8.3% 8.3%	 8.2%	 0.28
E	 3.9%	 3.9%	 3.8%	 3.8% 3.8% 3.7% 3.9%	 3.9%	 0.00
	
	
group	 present	 in	 PEG	 and	 a	 strong	 absorption	 band	 at												
2874	cm‐1	 indicating	 ‐O‐CH2‐CH2‐O‐	 linkage	 (ethylenedioxy)	of	
PEG	(Figure	4).	
	
3.6.	Uptake	 of	microspheres	 from	 various	 formulations	 by	
HME	cells	
	
The	 results	 of	 the	 microspheres	 uptake	 by	 HMECs	 are	
shown	 in	 Table	 4.	 Data	 indicates,	 microspheres	 from	
formulation		E		with		PEG		concentration		of		37.5	%		were		least		
engulfed	 by	 HME	 cells	 compared	 to	 the	 other	 microsphere	
formulations	containing	PEG.	This	difference	in	phagocytosis	is	
statistically	significant	when	compared	to	formulation	A,	which	
has	no	PEG.	(ANOVA	at	p	<0.05)	
	
	
	
Figure	3.	 IR	 spectrum	 of	 cross‐linked	 BSA	microspheres.	 Arrows	 indicate	
absorption	at	1645	cm‐1	and	at	3282	cm‐1	 from	carbonyl	group	and	amine	
and	hydroxyl	groups,	respectively.	
		
	
	
	
Figure	4.	 IR	 spectrum	of	 cross‐linked	BSA	microspheres	with	PEG.	Arrows	
indicate	 absorption	 at	 1105	 cm‐1,	 1650	 cm‐1	 and	 at	 3282	 cm‐1	 from	 ether	
group,	carbonyl	group	and	amine	and	hydroxyl	groups,	respectively.	
	
4.	Discussion	
	
PEG	is	a	non‐toxic	pharmaceutical	ingredient	and	is	readily	
removed	 by	 the	 kidneys.	 Addition	 of	 PEG,	 at	 37.5	 %	 (w/w)	
during	cross‐linking	of	BSA,	was	found	to	be	advantageous	as	it	
provides	significant	stealth	effect	to	the	microspheres.	Addition	
of	 very	 low	 amounts	 of	 PEG	 does	 not	 contribute	 to	 this	
property,	 and	 higher	 concentration	 (>50	 %)	 interfere	 with	
cross‐linking	 of	 BSA	 matrix.	 This	 could	 compromise	 the	
integrity	 of	 microspheres,	 resulting	 in	 shorter	 life	 span	 and	
works	 against	 sustained	 drug	 delivery.	 Embedding	 of	 PEG	 at	
37.5%	can	produce	a	partial	stealth	effect;	however,	 the	effect	
lasts	 the	 full	 life	 of	 the	 microsphere.	 This	 is	 because	 unlike	
surface	 cross‐linking,	 where	 only	 surface	 BSA	 is	 cross‐linked	
(once	the	surface	is	breached,	entire	content	of	microsphere	is	
dumped	resulting	 in	burst	 release),	 the	entire	matrix	 is	 cross‐
linked	 and	 embedding	 of	 PEG	 during	 cross‐linking	 helps	 in	
providing	 continual	 stealth	 effect	 even	when	 the	microsphere	
surface	 erodes	 over	 time.	 This	 simple	 embedding	 technology	
could	 enhance	 the	 delivery	 of	 variety	 of	 drugs	 and	 lengthens	
continual	 delivery	 with	 longer	 retention	 time	 in	 systemic	
circulation.	In	contrast,	other	methods	of	covalently	linking	PEG	
to	the	drug	molecules	results	in	new	a	moiety,	with	a	changed	
chemical	 structure	 and	 properties.	 The	 resultant	 is	 a	 rather	
large	molecule	that	could	have	a	pronounced	stealth	effect,	but	
very	 likely	 with	 obscured	 target	 binding	 sites	 and	 may	 not	
produce	 desired	 therapeutic	 outcomes.	 Therefore	 the	
PEGylated	drug	conjugate	must	cleave	in	order	for	drug	to	bind	
to	 the	 target	 or	 to	 enter	 the	 cell	 resulting	 in	 a	 desired	
pharmacological	 effect,	 which	 may	 not	 be	 feasible	 in	 many	
instances.		
	
5.	Conclusion	
	
The	 non‐covalent	 and	 easy	 PEG	 embedding	 technology	 in	
non‐toxic,	 cross‐linked	 BSA	 microspheres,	 described	 in	 this	
study	 is	 free	 from	 aforementioned	 defects	 and	 the	 drug	 will	
remain	 in	 the	 original	 chemical	 structure	 in	 the	 resulting	
microspheres.	The	observed	stealth	effect	to	the	microspheres	
could	prolong	their	systemic	circulation	for	improved	targeting	
and	enhanced	efficacy.	This	 technology	can	be	used	 to	 reduce	
the	 dosage	 schedule,	 which	 could	 result	 in	 better	 patient	
compliance	 and	 potentially	 be	 cost	 effective.	 Further	 studies	
are	required	to	improve	this	technique	for	even	more	compact	
and	 smaller	 microspheres	 with	 entrapped	 PEG	 to	 provide	
superior	 stealth	 effect,	 resulting	 in	 much	 longer	 systemic	
circulation	time	and	is	a	subject	for	future	communications.	
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